COVID-19

[Cell Reports] Scientists showed that octogenarians, a high-risk population, mount a sustained SARS-CoV-2 spike-specific IgG antibody response for 15 months following infection.

[Capricor Therapeutics] Capricor Therapeutics announced that its Phase II INSPIRE study evaluating a single-dose intravenous infusion of CAP-1002 as a potential treatment option for hospitalized patients with advanced symptoms of COVID-19 met its primary objective of safety.

[Frontiers in Immunology] The authors summarize current evidence from in vitro studies, animal models, and their clinical experience, to support stromal cell therapy in multiple clinical indications.

[Molecular Medicine] Based on evidence from the literature, as well as international scientific recommendations, the authors review the relationships between COVID-19, autoimmunity and patients with autoimmune rheumatic and musculoskeletal disease.

[Stem Cell Research & Therapy] Investigators focus on the proposed early and late therapeutic mechanisms of human amniotic epithelial cells and their exosomes to the injured organs.

[European Journal of Human Genetics] Investigators discovered an increased allelic expression pattern accompanied with overexpression of human leucocyte antigen (HLA)-B gene in SARS-CoV-2-infected human lung epithelial cells.